Boji Pharmaceutical (300404.SZ) announced first-half results, with net profit of 37.2005 million yuan to mother, an increase of 138.93% over the previous year

According to the Zhitong Finance App, Boji Pharmaceutical (300404.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 454 million yuan, an increase of 25.64% over the previous year. Net profit attributable to shareholders of listed companies was 37.20,500 yuan, an increase of 138.93% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 22.3911 million yuan, an increase of 86.77% over the previous year.

During the reporting period, the company added about 764 million yuan in business contracts. By the end of the reporting period, the amount of unconfirmed revenue from the contracts executed by the company was about 3,634 billion yuan.